CorVision® 4-year Follow-up (CorVision4yFU)
28. Mai 2026 aktualisiert von: Katerina Klimesova, Gemini Eye Clinic
Four Years Extended Follow-Up on CorVision® Bioengineered Corneal Microlens: Safety and Efficacy
The objective of the study is to assess the long-term safety and effectiveness of the CorVision® microlens implanted in presbyopic patients for the management of management of presbyopia and near vision impairment.
Approximately 100 patients in the Czech Republic will participate in this study.
The study was reviewed and approved by an independent research ethics committee and also by the State Institute for Drug Control (SÚKL).
The study will consist of a single visit during which standard, non-invasive, and painless examinations will be performed.
This visit will correspond to the 4-year follow-up visit of the original clinical trial.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Studientyp
Beobachtungs
Einschreibung (Tatsächlich)
95
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Zlín, Tschechien, 760 01
- Gemini Eye Clinic
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Probenahmeverfahren
Nicht-Wahrscheinlichkeitsprobe
Studienpopulation
The target population are patients who suffered from presbyopia and underwent the original CorVision clinical study are medically suitable to undertake the current clinical study investigation.
Beschreibung
Inclusion Criteria:
- Subjects must have undergone implantation of CorVision microlens under study protocol CMG-PRT-002.
- Provide informed consent
- Willing to participate in the ophthalmological examinations
Exclusion Criteria:
- Patients with severe ocular or general disorders that would prevent them from completed the visit.
- Patients not being able to understand and give informed consent.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Post-presbyopia correction with unilaterally implanted microlens
Presbyopic patients who have undergone implantation of the CorVision microlens according to study protocol CMG-PRT-002.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Uncorrected Near Visual Acuity of 0.3 logMAR or better
Zeitfenster: At least 4 years after the implantation
|
More than 65% of the eyes should have an Uncorrected Near Visual Acuity (UNVA) of 0.3 logMAR or better at 4 years postoperatively.
|
At least 4 years after the implantation
|
|
Implant removal
Zeitfenster: At least 4 years after the implantation
|
The incidence of implant rejection leading to implant removal should occur in no more than 3% of implanted eyes.
|
At least 4 years after the implantation
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Clinically significant corneal haze occurrence
Zeitfenster: At least 4 years after the implantation
|
Clinically significant corneal haze is defined as any new stromal clouding in or near the laser-created pocket that leads to a reduction in central corneal clarity/transparency, is visible upon slit-lamp examination, and is graded as ≥ 2 on a standardized corneal haze grading scale.
|
At least 4 years after the implantation
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Monocular Uncorrected Near Visual Acuity at Best Reading Distance
Zeitfenster: At least 4 years after the implantation
|
Change in monocular uncorrected near visual acuity and best reading distance over time
|
At least 4 years after the implantation
|
|
Monocular and Binocular Uncorrected Near Visual Acuity at 40 cm
Zeitfenster: At least 4 years after the implantation
|
Change in monocular and binocular Uncorrected Near Visual Acuity (UNVA) at 40 cm.
|
At least 4 years after the implantation
|
|
Monocular and Binocular Distance Corrected Near Visual Acuity
Zeitfenster: At least 4 years after the implantation
|
Change in monocular and binocular Distance Corrected Near Visual Acuity (DCNVA).
|
At least 4 years after the implantation
|
|
Monocular and Binocular Corrected Near Visual Acuity
Zeitfenster: At least 4 years after the implantation
|
Change in monocular and binocular Corrected Near Visual Acuity (CNVA) over time.
|
At least 4 years after the implantation
|
|
Monocular and Binocular Uncorrected Intermediate Visual Acuity (UIVA)
Zeitfenster: At least 4 years after the implantation
|
Change in monocular and binocular Uncorrected Intermediate Visual Acuity (UIVA) over time.
|
At least 4 years after the implantation
|
|
Monocular and Binocular Distance Corrected Intermediate Visual Acuity
Zeitfenster: At least 4 years after the implantation
|
Change in monocular and binocular Distance Corrected Intermediate Visual Acuity (DCIVA) over time.
|
At least 4 years after the implantation
|
|
Monocular and Binocular Uncorrected Distance Visual Acuity (UDVA)
Zeitfenster: At least 4 years after the implantation
|
Change in monocular Uncorrected Distance Visual Acuity (UDVA) over time.
|
At least 4 years after the implantation
|
|
Monocular and Binocular Corrected Distance Visual Acuity (CDVA)
Zeitfenster: At least 4 years after the implantation
|
Change in monocular and binocular Corrected Distance Visual Acuity (CDVA) over time.
|
At least 4 years after the implantation
|
|
Objective refraction
Zeitfenster: At least 4 years after the implantation
|
Change in objective refractive sphere and cylinder magnitude measured by autorefractometry.
|
At least 4 years after the implantation
|
|
Subjective refraction
Zeitfenster: At least 4 years after the implantation
|
Change in manifest refractive sphere and cylinder magnitude, measured in diopters (D).
|
At least 4 years after the implantation
|
|
Near addition
Zeitfenster: At least 4 years after the implantation
|
Change in near addition values over time.
|
At least 4 years after the implantation
|
|
Corneal Keratometry Measurements (K1, K2, and Kmean)
Zeitfenster: At least 4 years after the implantation
|
Change in corneal keratometry values, including K1, K2, and mean keratometry (Kmean), as measured by corneal topography over time. Change in keratometry K1, K2 and Kmean measured in diopters over time. |
At least 4 years after the implantation
|
|
Central Corneal Thickness (Pachymetry) Measurement
Zeitfenster: At least 4 years after the implantation
|
Change in central corneal thickness as measured by corneal pachymetry over time.
|
At least 4 years after the implantation
|
|
Endothelial Cell Density (Study Eye)
Zeitfenster: At least 4 years after the implantation
|
Change in endothelial cell density over time.
|
At least 4 years after the implantation
|
|
Intraocular Pressure (Study Eye)
Zeitfenster: At least 4 years after the implantation
|
Change in intraocular pressure over time.
|
At least 4 years after the implantation
|
|
Tear Film Break-Up Time (TBUT) Test
Zeitfenster: At least 4 years after the implantation
|
Change in tear film stability as measured by Tear Film Break-Up Time (TBUT) in units of seconds.
|
At least 4 years after the implantation
|
|
Tear Production (Schirmer Test)
Zeitfenster: At least 4 years after the implantation
|
Change in tear production as measured by the Schirmer test in units of mm.
|
At least 4 years after the implantation
|
|
Corneal Thickness Measurement Using Optical Coherence Tomography (OCT)
Zeitfenster: At least 4 years after the implantation
|
Change in corneal thickness measured at the corneal center in μm.
|
At least 4 years after the implantation
|
|
Abnormal findings at OCT
Zeitfenster: At least 4 years after the implantation
|
Incidence of abnormal findings on OCT.
|
At least 4 years after the implantation
|
|
Slit-lamp findings
Zeitfenster: At least 4 years after the implantation
|
Incidence of abnormal slit lamp findings (eyelid, conjunctiva, epithelium, stroma, central cornea clarity, cornea neovascularization, anterior chamber, iris, lens).
|
At least 4 years after the implantation
|
|
Contrast sensitivity
Zeitfenster: At least 4 years after the implantation
|
Determination of contrast sensitivity measured by CSV 1000 (Vector Vision) (changes from the pre-operative to the post-operative state and its stability over time will be investigated).
|
At least 4 years after the implantation
|
|
Defocus curve
Zeitfenster: At least 4 years after the implantation
|
Change in visual acuity measured at different defocus vergence levels during monocular defocus curve testing over time.
|
At least 4 years after the implantation
|
|
Aberrometry measurements using iTrace
Zeitfenster: At least 4 years after the implantation
|
Change in the total higher order aberrations (HOA) assessed by iTrace.
|
At least 4 years after the implantation
|
|
Subjective questionnaire QoV - patient satisfaction
Zeitfenster: At least 4 years after the implantation
|
Evaluation of patient satisfaction assessed on a scale
|
At least 4 years after the implantation
|
|
Subjective questionnaire QoV
Zeitfenster: At least 4 years after the implantation
|
Evaluation of patient satisfaction as assessed using the Quality of Vision (QoV) questionnaire scoring scale.
|
At least 4 years after the implantation
|
|
Adverse events incidence
Zeitfenster: At least 4 years after the implantation
|
Intraoperative and adverse events at each time point (numbers and percentages)
|
At least 4 years after the implantation
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
27. Juni 2025
Primärer Abschluss (Tatsächlich)
25. November 2025
Studienabschluss (Tatsächlich)
25. November 2025
Studienanmeldedaten
Zuerst eingereicht
15. Mai 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
28. Mai 2026
Zuerst gepostet (Tatsächlich)
3. Juni 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
3. Juni 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
28. Mai 2026
Zuletzt verifiziert
1. Mai 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CMG-PRT-002-1
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .